Ross Mudgway1,2, Carlos Chavez de Paz Villanueva1, Ann C Lin1, Maheswari Senthil1, Carlos A Garberoglio1, Sharon S Lum3,4. 1. Department of Surgery, Division of Surgical Oncology, School of Medicine, Loma Linda University, Loma Linda, CA, USA. 2. School of Medicine, University of California, Riverside, Riverside, CA, USA. 3. Department of Surgery, Division of Surgical Oncology, School of Medicine, Loma Linda University, Loma Linda, CA, USA. slum@llu.edu. 4. School of Medicine, University of California, Riverside, Riverside, CA, USA. slum@llu.edu.
Abstract
OBJECTIVE: We sought to examine the impact of primary tumor resection on survival in HER2+ stage IV breast cancer patients in the era of HER2 targeted therapy. METHODS: We conducted a retrospective cohort study of women with HER2+ stage IV breast cancer in the National Cancer Database from 2010 to 2012 comparing those who did and did not undergo definitive breast surgery. RESULTS: Of 3231 patients, treatment included primary site surgery in 35.0%; chemo/targeted therapy in 89.4%; endocrine therapy in 37.7%; and radiation in 31.8%. Surgery was associated with Medicare/other government (OR 1.36, 95% CI 1.03-1.81) or private insurance (OR 1.93, 95% CI 1.53-2.42) versus none/Medicaid, radiation (OR 2.10, 95% CI 1.76-2.51), chemo/targeted therapy (OR 1.99, 95% CI 1.47-2.70), and endocrine therapy (OR 1.73, 95% CI 1.40-2.14). Non-Hispanic Black versus White patients (OR 0.68, 95% CI 0.53-0.87) were less likely to have surgery. Overall mortality was associated with insurance (Medicare/other government versus none/Medicaid, HR 0.36, p < 0.0001), receipt of chemo/targeted therapy (HR 0.76, p = 0.008), endocrine therapy (HR 0.70, p = 0.0006), and radiation therapy (HR 1.33, p = 0.0009), NH Black versus White race/ethnicity (HR 1.39, p = 0.002), visceral versus bone-only metastases (HR 1.44, p = 0.0003), and lowest versus highest income quartile (HR 1.36, p = 0.01). Propensity score analysis showed surgery was associated with improved survival versus no surgery (HR 0.56, 95% CI 0.40-0.77). CONCLUSIONS: Surgery of the primary site for metastatic HER2+ breast cancer is associated with improved overall survival in selected patients.
OBJECTIVE: We sought to examine the impact of primary tumor resection on survival in HER2+ stage IV breast cancerpatients in the era of HER2 targeted therapy. METHODS: We conducted a retrospective cohort study of women with HER2+ stage IV breast cancer in the National Cancer Database from 2010 to 2012 comparing those who did and did not undergo definitive breast surgery. RESULTS: Of 3231 patients, treatment included primary site surgery in 35.0%; chemo/targeted therapy in 89.4%; endocrine therapy in 37.7%; and radiation in 31.8%. Surgery was associated with Medicare/other government (OR 1.36, 95% CI 1.03-1.81) or private insurance (OR 1.93, 95% CI 1.53-2.42) versus none/Medicaid, radiation (OR 2.10, 95% CI 1.76-2.51), chemo/targeted therapy (OR 1.99, 95% CI 1.47-2.70), and endocrine therapy (OR 1.73, 95% CI 1.40-2.14). Non-Hispanic Black versus White patients (OR 0.68, 95% CI 0.53-0.87) were less likely to have surgery. Overall mortality was associated with insurance (Medicare/other government versus none/Medicaid, HR 0.36, p < 0.0001), receipt of chemo/targeted therapy (HR 0.76, p = 0.008), endocrine therapy (HR 0.70, p = 0.0006), and radiation therapy (HR 1.33, p = 0.0009), NH Black versus White race/ethnicity (HR 1.39, p = 0.002), visceral versus bone-only metastases (HR 1.44, p = 0.0003), and lowest versus highest income quartile (HR 1.36, p = 0.01). Propensity score analysis showed surgery was associated with improved survival versus no surgery (HR 0.56, 95% CI 0.40-0.77). CONCLUSIONS: Surgery of the primary site for metastatic HER2+ breast cancer is associated with improved overall survival in selected patients.
Authors: Gildy V Babiera; Roshni Rao; Lei Feng; Funda Meric-Bernstam; Henry M Kuerer; S Eva Singletary; Kelly K Hunt; Merrick I Ross; Karin M Gwyn; Barry W Feig; Frederick C Ames; Gabriel N Hortobagyi Journal: Ann Surg Oncol Date: 2006-04-17 Impact factor: 5.344
Authors: Laura Dominici; Julie Najita; Melissa Hughes; Joyce Niland; Paul Marcom; Yu-Ning Wong; Bradford Carter; Sara Javid; Stephen Edge; Harold Burstein; Mehra Golshan Journal: Breast Cancer Res Treat Date: 2011-06-29 Impact factor: 4.872
Authors: Elisabetta Rapiti; Helena M Verkooijen; Georges Vlastos; Gerald Fioretta; Isabelle Neyroud-Caspar; André Pascal Sappino; Pierre O Chappuis; Christine Bouchardy Journal: J Clin Oncol Date: 2006-05-15 Impact factor: 44.544
Authors: Andrea C Bafford; Harold J Burstein; Christina R Barkley; Barbara L Smith; Stuart Lipsitz; James D Iglehart; Eric P Winer; Mehra Golshan Journal: Breast Cancer Res Treat Date: 2008-06-26 Impact factor: 4.872
Authors: Ryan C Fields; Donna B Jeffe; Kathryn Trinkaus; Qin Zhang; Carey Arthur; Rebecca Aft; Jill R Dietz; Timothy J Eberlein; William E Gillanders; Julie A Margenthaler Journal: Ann Surg Oncol Date: 2007-08-09 Impact factor: 5.344
Authors: Jennifer Gnerlich; Donna B Jeffe; Anjali D Deshpande; Courtney Beers; Christina Zander; Julie A Margenthaler Journal: Ann Surg Oncol Date: 2007-05-24 Impact factor: 5.344